- CLIA
About
3billion provides rare disease genetic diagnostic services and newborn genetic screening services. It serves patients, families, clinicians, and partners from its site in Seoul, South Korea, with support for customers around the world.
Services
3B-GENOME
Whole-genome sequencing-based genetic testing for rare disease diagnosis, with automated reanalysis and raw data included.
3B-EXOME
Exome-focused genetic testing for rare disease diagnosis, with automated reanalysis and raw data included.
3B-VARIANT
Sanger sequencing to confirm a specific variant in a patient or family member.
3B-INTERPRETER
Genomic data analysis and interpretation service for user-generated FASTQ data, with a clinical report.
GEBRA™
Variant interpretation and diagnosis platform that turns VCF data into a final clinical report.
Reanalysis
Automatic reanalysis of previously undiagnosed rare disease cases using updated databases, AI, and expert review.
Drug discovery
AI-based drug discovery work for rare diseases, including target discovery, pocket discovery, and compound design.
Newborn genetic screening
Genetic screening services for newborns, as named in the service terms.
3B-NEO
Newborn genetic screening service.
EVIDENCE
Automated genetic variant interpretation system.
3Cnet
Variant pathogenicity prediction tool.
- Turnaround
- Within 4 weeks · Results within 2 weeks · Initial response within one business day · We will respond within 24 business hours · 3B-GENOME & 3B-EXOME results within 4 weeks · EVIDENCE classifies ~100,000 WES variants in 5 minutes on average
- What to send
- FASTQ data · Blood · Saliva · Other specimens · Sample kit included for ordering · Biological samples such as blood, saliva, or other specimens
Capabilities
- Assays and studies
- Rare disease genetic testing · Variant interpretation · Reanalysis · Genomic data analysis · Sanger confirmation · Newborn genetic screening · WGS · WES · Pathogenicity prediction
- Scale and capacity
- 70+ countries where testing is available · 2,200+ clinicians who have used their testing · 100,000+ patients who have received test results · 62,000+ patients' genomes tested · 40,000+ patients' genomes tested · 20,000+ patients' genomes tested · 2,200+ clinicians who have used the testing · 12+ global pharma partners
- Therapeutic areas
- Rare diseases · Reproductive loss · Fetal death · Inherited risk · Orphan drugs
Instruments and platforms
- Illumina NovaSeq X
Modalities and species
- Modalities
- Small molecule
- Species and models
- Human · Illumina NovaSeq X
Certifications
As the company states them, with the certificate or registry record where there is one.
CLIASelf-reported
As listed: CLIA (ID # 99D2274041); CLIA certified
CAPSelf-reported
As listed: CAP (License # 8750906); CAP accredited
Industries served
- Pharma
- Rare disease diagnostics
Company
- Founded
- 2016
Locations
- Based in
- Seoul, South Korea
- Sites
- Seoul, South Korea
- Serves
- worldwide, 70+ countries
Contacts
- General contact
- support@3billion.io on their site
- Phone
- +82-2-6258-3770
Similar labs
Work here? Claim this listing